tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

CANF Stock Latest News

Can-Fite Secures Israeli Patent to Bolster Namodenoson Anti-Obesity Franchise
Company AnnouncementsCan-Fite Secures Israeli Patent to Bolster Namodenoson Anti-Obesity Franchise
3d ago
6K
CANF
Can-Fite BioPharma announces Israeli patent allowance for namodenoson
PremiumThe Fly
Can-Fite BioPharma announces Israeli patent allowance for namodenoson
3d ago
CANF
Can-Fite BioPharma Shareholders Approve All Proposals at March 10 Special Meeting
PremiumCompany Announcements
Can-Fite BioPharma Shareholders Approve All Proposals at March 10 Special Meeting
10d ago
6K
CANF
Can-Fite BioPharma Secures $4 Million via Repriced Warrant Exercise to Fund Clinical Pipeline
PremiumCompany Announcements
Can-Fite BioPharma Secures $4 Million via Repriced Warrant Exercise to Fund Clinical Pipeline
15d ago
6K
CANF
Can-Fite’s Namodenoson Clears Phase 2a Safety Bar in Advanced Pancreatic Cancer
PremiumCompany Announcements
Can-Fite’s Namodenoson Clears Phase 2a Safety Bar in Advanced Pancreatic Cancer
16d ago
6K
CANF
Can-Fite BioPharma says namodenoson meets primary endpoint in Phase 2a study
PremiumThe FlyCan-Fite BioPharma says namodenoson meets primary endpoint in Phase 2a study
16d ago
CANF
Can-Fite BioPharma Adjourns Special Shareholders’ Meeting to March 10, 2026
Premium
Company Announcements
Can-Fite BioPharma Adjourns Special Shareholders’ Meeting to March 10, 2026
17d ago
6K
CANF
Can-Fite Targets Rare Kidney Disease With New Phase 2 Lowe Syndrome Trial
Premium
Company Announcements
Can-Fite Targets Rare Kidney Disease With New Phase 2 Lowe Syndrome Trial
30d ago
CANF
Can-Fite Showcases Namodenoson Anti-Obesity Data in Peer-Reviewed Journal
PremiumCompany Announcements
Can-Fite Showcases Namodenoson Anti-Obesity Data in Peer-Reviewed Journal
1M ago
6K
CANF
Can-Fite BioPharma announces publication of anti-obesity effect of namodenoson
PremiumThe Fly
Can-Fite BioPharma announces publication of anti-obesity effect of namodenoson
1M ago
CANF
Can-Fite BioPharma Wins Canadian Patent Allowance for Namodenoson Obesity Use
PremiumCompany Announcements
Can-Fite BioPharma Wins Canadian Patent Allowance for Namodenoson Obesity Use
1M ago
6K
CANF
Can-Fite BioPharma receives Canadian patent allowance for namodenoson
PremiumThe Fly
Can-Fite BioPharma receives Canadian patent allowance for namodenoson
1M ago
CANF
Can-Fite Reports Successful Liver Transplant After Compassionate Use of Namodenoson
PremiumCompany AnnouncementsCan-Fite Reports Successful Liver Transplant After Compassionate Use of Namodenoson
1M ago
6K
CANF
Can-Fite announces patient with liver cirrhosis treated with Namodenoson
Premium
The Fly
Can-Fite announces patient with liver cirrhosis treated with Namodenoson
1M ago
CANF
Can-Fite BioPharma Calls March 3 Special Meeting to Address NYSE Audit Committee Non-Compliance
Premium
Company Announcements
Can-Fite BioPharma Calls March 3 Special Meeting to Address NYSE Audit Committee Non-Compliance
2M ago
6K
CANF
Can-Fite Completes Enrollment in Phase 2a Pancreatic Cancer Trial of Namodenoson
PremiumCompany Announcements
Can-Fite Completes Enrollment in Phase 2a Pancreatic Cancer Trial of Namodenoson
2M ago
6K
CANF
Can-Fite completes patient enrollment in Phase 2a study of Namodenoson
PremiumThe Fly
Can-Fite completes patient enrollment in Phase 2a study of Namodenoson
2M ago
CANF
Can-Fite BioPharma Discloses Resignation of Director Yaacov Goldman
PremiumCompany Announcements
Can-Fite BioPharma Discloses Resignation of Director Yaacov Goldman
2M ago
6K
CANF
Upcoming Stock Splits This Week (January 5 to January 9) – Stay Invested
PremiumMarket News
Upcoming Stock Splits This Week (January 5 to January 9) – Stay Invested
2M ago
ICU
TRT
Can-Fite BioPharma Secures Brazilian Patent for A3AR-Based Sexual Dysfunction Therapy
PremiumCompany AnnouncementsCan-Fite BioPharma Secures Brazilian Patent for A3AR-Based Sexual Dysfunction Therapy
3M ago
6K
CANF
Can-Fite BioPharma downgraded to Hold from Buy at D. Boral Capital
Premium
The Fly
Can-Fite BioPharma downgraded to Hold from Buy at D. Boral Capital
3M ago
CANF
Can-Fite BioPharma Sets 1-for-3,000 Reverse Share Split and ADS Ratio Change Effective Early January 2026
Premium
Company Announcements
Can-Fite BioPharma Sets 1-for-3,000 Reverse Share Split and ADS Ratio Change Effective Early January 2026
3M ago
6K
CANF

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >